Ventripoint's VMS Systems wins expanded FDA indication
Ventripoint Diagnostics’ VMS heart analysis system has been granted an expanded FDA indication for right ventricle volume and ejection fraction assessment, the Bellevue, Wash., devicemaker announced Friday.
Previously, the system was limited for use on pulmonary arterial hypertension patients. An RV diagnostic can be an important predictive tool for heart disease and enable cardiologists to decide when to evaluate a patient.
The device is the only one available that provides as accurate results as an MRI, Ventripoint says. An MRI takes hours while a CT scan involves high doses of radiation, and both methods may be unusable in patients with kidney issues.
Heart disease is the leading cause of death worldwide. — Jason Scott